Podcasts about myasthenia gravis foundation

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 30-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-treatment-options/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org Copyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

In this episode Dr. Daniel Correa talks with jazz musician John Stein about the symptoms he experienced that led to hospitalization and a myasthenia gravis diagnosis. John also shares his recovery and rehab journey after his hospitalization. Next, Dr. Correa sits down with Dr. Carolina Barnett-Tapia, neurologist and associate professor of neurology at the Institute of Health Policy, Management, and Evaluation at the University of Toronto. Dr. Barnett-Tapia explains what myasthenia gravis is and why it may present differently in each person, as well as important considerations for caregivers when someone is newly diagnosed with the condition.  A special thank you to John Stein for permission to feature the title track “No Goodbyes” from his upcoming album release in this week's episode. Available on Spotify and Apple Music.  Additional Resources  https://johnstein.com/   Brain & Life: Physical Activity Helps Manage Myasthenia Gravis   Learn more about myasthenia gravis   Myasthenia Gravis Foundation of America   Other Myasthenia Gravis Brain & Life Podcast Episodes:  Brain & Life Podcast: Ashley Brooks on Advocating for Herself and Others with Myasthenia Gravis   Brain & Life Podcast: Soap Opera Star Suzanne Rogers Brings Awareness to Myasthenia Gravis  We want to hear from you!  Have a question or want to hear a topic featured on the Brain & Life Podcast?  Record a voicemail at 612-928-6206  Email us at BLpodcast@brainandlife.org  Social Media:    Guest: John Stein https://johnstein.com/; Department of Medicine University of Toronto @UofT_DoM (Twitter)  Host: Dr. Daniel Correa @neurodrcorrea 

Parmi les affections rares et peu connues, la myasthénie occupe une place importante et s'avère particulièrement handicapante au quotidien. Provoquant une faiblesse généralisée des muscles du squelette et leur fatigue plus rapide que la normale, la maladie affecte profondément la qualité de vie des personnes touchées. Quels sont les mécanismes à l'œuvre dans cette affection auto-immune, et ses conséquences ?Les symptômes qui caractérisent la myasthénieLa myasthenia gravis, plus couramment appelée myasthénie, est principalement caractérisée par une faiblesse musculaire aggravée après une période d'activité et améliorée après une période de repos. Concrètement, les muscles squelettiques ont du mal à se contracter puissamment et durablement. Les muscles les plus touchés sont ceux qui contrôlent les yeux et les paupières, ceux qui permettent d'afficher plusieurs expressions du visage, de mâcher, de déglutir ou de respirer.Les gestes les plus élémentaires du quotidien posent parfois de véritables défis. Les personnes très touchées par la maladie ont du mal à parler, manger ou se déplacer. Il faut savoir que, d'après la Myasthenia Gravis Foundation of America, les symptômes fluctuent beaucoup, ajoutant un caractère imprévisible à l'affection qui la rend encore plus complexe à vivre. Par exemple, une personne atteinte peut se sentir très bien la moitié de la journée puis incapable de faire quoi que ce soit quelques heures plus tard.Comment se déclenche la myasthénie ?Liée à un défaut de communication entre les nerfs et les muscles, la myasthénie se manifeste à tout âge, mais plus couramment chez les femmes jeunes ayant entre 20 et 40 ans, et chez les hommes âgés ayant entre 60 et 80 ans. Elle n'est pas déclenchée par un facteur particulier, mais peut s'aggraver en fonction d'éléments tels qu'une infection, un stress, une fatigue importante, une chirurgie ou des modifications hormonales telles qu'il en apparait pendant la grossesse. La personne subit alors une faiblesse musculaire plus importante, rendant la myasthénie très difficile à vivre.La prise de médicaments joue aussi un rôle sur l'aggravation des symptômes. Les antibiotiques, les bétabloquants et les anesthésiques peuvent favoriser une faiblesse musculaire plus marquée.Les conséquences de la myasthénie sur la vie des patientsAu-delà des limites physiques qu'impose la maladie aux patients, sa portée psychologique et sociale entraine d'autres conséquences délétères. L'isolement social, le stress psychologique, le manque de confiance en ses propres capacités peuvent à leur tour engendrer de l'anxiété et de la dépression. Il est donc primordial pour les personnes souffrant de myasthénie d'être accompagnées tant sur le plan médical que psychologique et social, afin de conserver une qualité de vie correcte. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Parmi les affections rares et peu connues, la myasthénie occupe une place importante et s'avère particulièrement handicapante au quotidien. Provoquant une faiblesse généralisée des muscles du squelette et leur fatigue plus rapide que la normale, la maladie affecte profondément la qualité de vie des personnes touchées. Quels sont les mécanismes à l'œuvre dans cette affection auto-immune, et ses conséquences ? Les symptômes qui caractérisent la myasthénie La myasthenia gravis, plus couramment appelée myasthénie, est principalement caractérisée par une faiblesse musculaire aggravée après une période d'activité et améliorée après une période de repos. Concrètement, les muscles squelettiques ont du mal à se contracter puissamment et durablement. Les muscles les plus touchés sont ceux qui contrôlent les yeux et les paupières, ceux qui permettent d'afficher plusieurs expressions du visage, de mâcher, de déglutir ou de respirer. Les gestes les plus élémentaires du quotidien posent parfois de véritables défis. Les personnes très touchées par la maladie ont du mal à parler, manger ou se déplacer. Il faut savoir que, d'après la Myasthenia Gravis Foundation of America, les symptômes fluctuent beaucoup, ajoutant un caractère imprévisible à l'affection qui la rend encore plus complexe à vivre. Par exemple, une personne atteinte peut se sentir très bien la moitié de la journée puis incapable de faire quoi que ce soit quelques heures plus tard. Comment se déclenche la myasthénie ? Liée à un défaut de communication entre les nerfs et les muscles, la myasthénie se manifeste à tout âge, mais plus couramment chez les femmes jeunes ayant entre 20 et 40 ans, et chez les hommes âgés ayant entre 60 et 80 ans. Elle n'est pas déclenchée par un facteur particulier, mais peut s'aggraver en fonction d'éléments tels qu'une infection, un stress, une fatigue importante, une chirurgie ou des modifications hormonales telles qu'il en apparait pendant la grossesse. La personne subit alors une faiblesse musculaire plus importante, rendant la myasthénie très difficile à vivre. La prise de médicaments joue aussi un rôle sur l'aggravation des symptômes. Les antibiotiques, les bétabloquants et les anesthésiques peuvent favoriser une faiblesse musculaire plus marquée. Les conséquences de la myasthénie sur la vie des patients Au-delà des limites physiques qu'impose la maladie aux patients, sa portée psychologique et sociale entraine d'autres conséquences délétères. L'isolement social, le stress psychologique, le manque de confiance en ses propres capacités peuvent à leur tour engendrer de l'anxiété et de la dépression. Il est donc primordial pour les personnes souffrant de myasthénie d'être accompagnées tant sur le plan médical que psychologique et social, afin de conserver une qualité de vie correcte. Learn more about your ad choices. Visit megaphone.fm/adchoices

Toni Gitles, founder and CEO of Caregiver Empowerment, Heart Light Enterprises LLC shares her 14-year caregiving story and provides a continuation of our conversation from her first appearance on the podcast in Season #2 in the episode entitled "And Then I Danced". Toni shares that caring for a family member is a act of love that comes from the heart and she talks about the importance of relationship, communication, happiness and love - all important to help make the experience into a journey of connection, advocacy and discovery. Toni is an international speaker and has contributed to three books on caregiving and lifestyle management. She has authored a new book 21 Mistakes Caregivers Make and How to Avoid Them: Solutions and Strategies to Reduce Stress and Increase Happiness, available September 2023. In her free time, Toni enjoys gardening, playing with her Maltese dog, and competitive ballroom dancing. She is co-founder of the Dementia-Friendly Dining in Central Florida and co-ordinates caregiver conferences on Dementia-Friendly Cruises. In 2022 she received the Emerging Leadership Award from the Myasthenia Gravis Foundation of America. You can visit her website or find her on social media: LinkedIn; Facebook; Instagram; and Twitter.

Today we have a special additional episode this month as we are talking with Dr. Jonathan Strober the Director of the Neuromuscular Clinic at Benioff Children's Hospital at the University of California San Francisco as well as Meredith O'Connor the Assistant Vice President for Patient Engagement, Advocacy & Policy for Myasthenia Gravis Foundation of America. Normally our episodes are geared towards the families and hearing their stories but today we are going to get an expert look…a sort of behind the scenes glimpse from the professionals that are associated with Myasthenia Gravis.

Welcome to episode 3 of the “Neuroscience series” on the “Love at First Science” Podcast where Dr. Saperstein and I dive into the yet unknown world of Hypermobility. Topics covered: - Dr. Saperstein's background and how he got to work in this field; - Hypochondria and Hypermobility; - What influences Hypermobility? - Insightful recommendations to empower the Hypermobile community; - What are the Dysautonomia symptoms and some tips - Hypermobile brain - Anxiety and Hypermobility - Final message from Dr. Saperstein LEARN MORE ABOUT DR. DAVID SAPERSTEIN! Dr. David Saperstein is a veteran of the U.S. Air Force that was born in Providence, Rhode Island. He attended medical school at Boston University School of Medicine. Later he completed postdoctoral training in Texas in Neuromuscular Disease and did a Clinical Neurophysiology Fellowship. He holds professional memberships with American Academy of Neurology, American Association of Electrodiagnostic Medicine, World Muscle Society, Peripheral Nerve Society, Arizona Neurological Society, Maricopa County Medical Society, and the Arizona Medical Society. Being involved in the community is important to Dr. Saperstein and he has previously sat on 14 different Local and National Committees. He currently sits on three National Committees as a Member of the Medical Advisory Board of the Neuropathy Action Foundation, the GBS/CIDP Foundation International, and the Myasthenia Gravis Foundation of America. Dr. Saperstein has spent a significant amount of time studying, researching, and caring for over 2,500 patients with EDS, POTS, and other related conditions. Placing the primary focus of the Center on these specific conditions, has allowed him and his team to attain the knowledge and skills necessary to fully understand, diagnose, and manage EDS and POTS patients. Dr. Saperstein takes pride in listening to his patients, being empathetic, and providing thorough care to them. In recognition of this, Dr. Saperstein was the 2021 recipient of the Community Choice Award for Healthcare Professionals from The Ehlers-Danlos Society. Being recognized this way was such a huge honor to him and you will see the plaque displayed in the office upon your visit. In addition to his experience with patients with EDS and other related conditions, he has over 20 years' experience as a neurologist, giving him valuable insight into some of the particularly troubling and more esoteric complications, such as Chiari malformation, CCI, headaches, cognitive disorders, and neuropathy. Dr. Saperstein also has over two decades experience in diagnosing and managing patients with complex nerve and muscle conditions such as CIDP (and other immune-mediated neuropathies), myasthenia gravis and myositis. He is available to provide care for patients with these conditions as well. David Saperstein, MD Board certified in Neurology, Neuromuscular Medicine, Clinical Neurophysiology and Electrodiagnostic Medicine Clinical Associate Professor of Neurology, University of Arizona College of Medicine, Phoenix, AZ ---------------------DR. SAPERSTEIN'S SOCIALS: Check out & learn more with Dr. David Saperstein: Dr. Saperstein Instagram Dr. Saperstein website THE BOOK! If you want to deepen your knowledge on Hypermobility, you can buy my book Too flexible to feel good HERE CELEST'S SOCIALS My Socials: Celest's Instagram Celest's Website

On Today's episode, we have the privilege of interviewing Sean on his remarkable story of getting diagnosed with Myasthenia Gravis. While his path wasn't ideal, Sean is on the road to recovery and is enjoying the beginning stages of remission! Find Sean on Reddit as /u/SeanRok on the subreddit /r/MyastheniaGravis. If you would like to be interviewed for the podcast please send an email to MyMyastheniaPod@gmail.com and we can discuss having you on the show!  Don't forget June is Myasthenia Gravis Awareness Month. To find out more, visit the Myasthenia Gravis Foundation here: https://myasthenia.org/Make-an-Impact/Turn-Awareness-into-Action  --- Support this podcast: https://anchor.fm/mymyasthenia/support

Patients with autoimmune diseases are at higher risk for severe complications of COVID-19 which means that social distancing guidelines may be in place for autoimmune patients longer than the general public, joining me with information about a new online platform to offer personalized resources and unite patients with Myasthenia Gravis in a time of social distancing,  Dr. Ericka Greene, Program Director, Neurology Residency and Neuromuscular Medicine Residence, Houston Methodist Hospital in Houston, Texas and Rachel Higgins, patient and Myasthenia Gravis Foundation of America Community Leader, from Austin, Texas.

Patients with autoimmune diseases are at higher risk for severe complications of COVID-19 which means that social distancing guidelines may be in place for autoimmune patients longer than the general public, joining me with information about a new online platform to offer personalized resources and unite patients with Myasthenia Gravis in a time of social distancing,  Dr. Ericka Greene, Program Director, Neurology Residency and Neuromuscular Medicine Residence, Houston Methodist Hospital in Houston, Texas and Rachel Higgins, patient and Myasthenia Gravis Foundation of America Community Leader, from Austin, Texas.

Talked with Melissa and Michael about the Myasthenia Gravis Foundation of America. A lot of people haven't heard of MG. What is myasthenia gravis (MG)? According to their website:Myasthenia gravis (pronounced My-as-theen-ee-a grav-us) comes from the Greek and Latin words meaning "grave muscular weakness." The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. The website has a wealth of information for patients, caregivers, medical professionals and volunteers. Listeners can get information about education, research, support, info on clinical trials, latest meds, and more at https://myasthenia.org/

1) ALS studies and 2) Topic of the month: Evaluation of polyneuropathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns with Dr. Michael Benatar about his paper on studies in ALS. Dr. Jennifer Fugate is reading our e-Pearl of the week about Gradenigo syndrome. In the next part of the podcast Dr. Ted Burns interviews Drs. Michelle L. Mauermann and P. James Dyck about evaluation of polyneuropathy, basics. The participants had nothing to disclose except Drs. Burns, Benatar, Fugate and Mauermann.Dr. Ted Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (35% effort); and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Benatar serves as an editorial board member for Journal Watch Neurology; serves on the scientific advisory board for Cytokinetics; is a consultant for Cytokinetics and Asubio Pharmaceuticals Inc.; receives royalties from the publication of the books (1) Neuromuscular Disease: Evidence and Analysis in Clinical Neurology, (2) BluePrints in Neurology, (3) Field of Vision; receives travel funding from the (1) American Academy of Neurology, (2) Myasthenia Gravis Foundation of America; receives research support from the CytRx Corporation, Food and Drug Administration, Muscular Dystrophy Association, ALS Association, Woodruff Foundation and the NIH; involved in legal proceedings with Sutter, O'Connel and Farchione Attorneys as well as Parker Waichmann LLP. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Mauermann receives research support from Pfizer Inc and the NIH.

1) C90RF72 mutations and 2) Topic of the month: Bedside Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns with Drs. Sharon Sha and Carol Dobson-Stone about their papers on frontotemporal dementia. Dr. Stacey Clardy is reading our e-Pearl of the week about Hanes sign. In the next part of the podcast Dr. Beau Bruce interviews Dr. Randy Kardon about relative afferent papillary defect. Dr. Bruce will interview Dr. Kardon next week about "big pupil" consult. The participants had nothing to disclose except Drs. Burns, Dobson-Stone, Clardy, Bruce and Kardon.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Dobson-Stone receives research funding from the National Health and Medical Research Council (Australia).Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bruce received research funding from the NIH.Dr. Kardon serves on the editorial board for Journal of Neuro-ophthalmology and Archives of Ophthalmology; has patents for method of characterizing focal pupil responses to light and method of assessing retinal function using infrared optical signals in response to light; receives royalties for the publication of Tissues and Organs: A text-atlas of scanning electron microscopy and for use of micrographs in other textbooks; is a consultant for Novartis Pharmaceuticals Ltd; receives research support from the Department of Veterans Affairs Iowa City Center of Excellence for the Prevention and Treatment of Visual Loss, Department of Defense Vision Research Program (TATRC) and Department of Veterans Affairs Rehabilitation Division.

1) Reportable neurologic disorders and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Shanna Patterson interviews Dr. Farrah Mateen about her paper on reportable neurologic disorders in refugee camps. Dr. Chafic Karam is reading our e-Pearl of the week about sporadic amyotrophic lateral sclerosis. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Ken Heilman about some of the neurologic diseases that cause apraxia. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Karam, Burns and Heilman.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Adult neurology training and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Nina Schor about her paper on adult neurology training during child neurology residency. Dr. Chafic Karam is reading our e-Pearl of the week about transthyretin amyloidosis. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about dissociation and conceptual apraxia. The participants had nothing to disclose except Drs. Goodkin, Schor, Karam, Burns and Heilman.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; received royalties for an entry in Up-to-date entitled: The choking game and other strangulation activities in children and adolescents and is funded by NIH grants.Dr. Schor serves as an editorial board member for MedLink Neurology, Neurology, Pediatric Neurology and Journal of Child Neurology; receives royalties for the publication of Nelson's Textbook of Pediatrics and Swaiman's Pediatric Neurology: Principles and Practice and is funded by the NIH.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Antiplatelets versus anticoagulation and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Hugh Markus about his paper on antiplatelets versus anticoagulation for dissection. Dr. Chafic Karam is reading our e-Pearl of the week about caffeine and Parkinson disease. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about limb-kinetic, ideomotor and ideational apraxias and how it might come to our attention. The participants had nothing to disclose except Drs. Markus, Karam, Burns and Heilman.Dr. Markus has served on scientific advisory boards for W. L. Gore & Associates, Inc., Boehringer Ingelheim, and Sanofi-Synthélabo; serves on the editorial boards of Stroke and Clinical Neurology and Neurosurgery; receives publishing royalties for Stroke Medicine (Oxford University Press, 2010); served as a consultant for Archimex SAS and Shire plc; and has received research support from Archimex SAS, Shire plc, MRC UK, the Stroke Association, the European Union, Wellcome Trust and the British heart Foundation.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Creutzfeldt-Jakob disease and 2) Topic of the month: Apraxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Clive Hamlin about his paper on diagnosis of Creutzfeldt-Jakob disease. Dr. Chafic Karam is reading our e-Pearl of the week about POEMS syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Ken Heilman about definitions for apraxia and various forms of apraxia. Dr. Burns will interview Dr. Heilman about other forms of apraxias over the next three weeks. The participants had nothing to disclose except Drs. Burns, Karam, and Heilman.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Heilman serves as an editorial board member for ACTA Neuropsychologia, The Journal of Contemporary Neurology, Journal of the International Neuropsychological, Neurocase, Neuropsychiatry, Neuropsychology and Behavioral Neurology-Cognitive and Behavioral Neurology, Brain and Cognition, Journal of Neuropsychology and Journal of Clinical Neurology; receives royalties for the publication of Clinical Neuropsychology, fifth edition, PGY1: Lessons in Caring, Neurological Therapeutics : Principles and Practice second edition, Creativity and the Brain, Clinical Neuropsychology, fourth edition, Neurological Therapeutics : Principles and Practice, The Matter of Mind, A Neurologist's View of Brain Behavior Relationships, Apraxia, Helping People with Memory Disorders: A Guide for You and Your Family, Clinical Neuropsychology, third edition, Clinical Neuropsychology, second edition, Neuropsychology of Human Emotion, Clinical Neuropsychology and The Differential Diagnosis of Neurological Diseases; and receives funding from current (active) funded research proposals, Alzheimer's Disease Initiative State of Florida, Dept. of Elder Affairs, Memory Disorder Clinics, and the NIH.

1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Bleeding risk after stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michael Knoflach about his paper on an increased bleeding risk after stroke thrombolysis. Dr. Jennifer Fugate is reading our e-Pearl of the week about hummingbird sign in PSP. In the next part of the podcast Dr. Alberto Espay interviews Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with our interview with Drs. Titulaer and Vincent. The participants had nothing to disclose except Drs. Kissela, Kiechl, Fugate, Espay and Mehler.Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.

1) Progesterone versus placebo therapy for women with epilepsy and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chenjie Xia interviews Dr. Andy Herzog about his paper on progesterone versus placebo therapy for women with epilepsy. Dr. Stacey Clardy is reading our e-Pearl of the week about myotonia congenita. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about bedside testing of memory. The participants had nothing to disclose except Drs. Herzog, Clardy, Burns and Buonomano.Dr. Herzog serves as an editorial board member of Epilepsy & Behavior.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

1) Measures of health-related quality of life and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Cella about his paper on measures of health-related quality of life. Dr. Stacey Clardy is reading our e-Pearl of the week about frontotemporal dementia. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about major categories of memory. Next week they will discuss bedside testing of memory. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cella serves on the scientific advisory boards of the Moffitt Cancer Center, NCI Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee, serves as Associate Editor of The Journal of Supportive Oncology; is a consultant for Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, and GlaxoSmithKline; receives royalties from Up-to-Date annual review of Quality of life measures; receives research support from Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, GlaxoSmithKline and AVEO Pharmaceuticals, Inc.; and is funded by the NIH.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

1) Small fiber neuropathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Waxman about his paper on small fiber neuropathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about diffusion-weighted imaging. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about other biomarkers for mild cognitive impairment and Alzheimer disease. Next week they will discuss preclinical Alzheimer disease. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Waxman serves on the editorial boards of Clinical Neuroscience, The Neurologist, Neurobiology of Disease, Clinical Neurology and Neurosurgery, SYNAPSE, Molecular Neurobiology, Clinical Neuroscience Research, Neuron-Glia Biology, Neurotherapeutics, Trends in Molecular Medicine, Molecular Pain and Channels; served on the editorial board Journal of Neurotrauma; serves on the scientific advisory board for Brain and Nature Reviews Neurology; Editor-in-Chief of The Neuroscientist and Neuroscience Letters; Editor of The Journal of Physiology; Section Head Multiple Sclerosis, Faculty of 1000 Medicine; is or has been a consultant for Cardiome Pharmaceutical, Bristol-Myers Squibb, Vertex Pharmaceutical, ChromaCell and DaiNippon Sumitomo Pharmaceuticals; receives research support from Pfizer Inc., The Erythromelalgia Association and Department of Veterans Affairs; holds stock options in SITE ONE Research for serving on its Advisory Board and is listed as an inventor for a patent held by Yale University on the Invention of sodium channel NaV1.9.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society.Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc.

1) Developing epilepsy after febrile seizures and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Levy Sander about his paper on developing epilepsy after febrile seizures. Dr. Chafic Karam is reading our e-Pearl of the week about neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Dr. Jeff Burns about the link between dementia and obesity. Next week, Dr. Brett Kissela will interview Dr. Mitch Elkind about stroke and obesity. The participants had nothing to disclose except Prof. Sander, Drs. Karam, Ted Burns, and Jeff Burns.Prof. Sander serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., ViroPharma Incorporated, and UCB; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology, Epileptic Disorders, and Epilepsia; serves on the speakers' bureaus of UCB and GlaxoSmithKline; received research support from UCB (institutional), the NIH, CBRC, European Union Seventh Framework Programme, Wellcome Trust, National Epilepsie Fonds Nederland, and The Brain Research Trust; and his current post is endowed by the UK Epilepsy Society. Dr. Karam serves on the editorial team for the Neurology Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.

1) Long term remission in CIDP and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Filip Eftimov about his paper on long term remission in CIDP. Dr. Chafic Karam is reading our e-Pearl of the week about acute basilar artery occlusion. In the next part of the podcast Dr. Ted Burns interviews Dr. Beau Bruce about obesity in Idiopathic intracranial hypertension. Drs. Burns & Kissela with interview others about obesity and the neurology patient. The participants had nothing to disclose except Drs. Burns, Eftimov, Karam, and Bruce.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Eftimov received payment from Sanquin Blood Supply Foundation for a single lecture to nurses providing home-care immunoglobulin therapy.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Bruce receives research support as recipientof AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 & KL2-RR025009.

1) Evidence-based guideline on intravenous immunoglobulin and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Huned Patwa about his paper on evidence-based guideline on intravenous immunoglobulin. Dr. Stacey Clardy is reading our e-Pearl of the week about chronic migraine prophylaxis. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Clardy, Burns, Groopman and Hartzband.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Patwa was an investigator in the ICE trial comparing IGIV with placebo for CIDP.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) Lamotrigine and aseptic meningitis and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michaela Tegan Chatman interviews Drs. Simms, Kortepeter and Avigan about their paper on lamotrigine and aseptic meningitis. Dr. Stacey Clardy is reading our e-Pearl of the week about pregnancy on the course of neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about risk-benefit ratios. Next week, Dr. Burns will interview Drs Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Simms, Kortepeter, Avigan, Clardy, Burns, Groopman and Hartzband.Dr. Simms is employed at U.S. Food and Drug Administration. Dr. Kortepeter is employed at U.S. Food and Drug Administration. Dr. Avigan is employed at U.S. Food and Drug Administration. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) Cognition in the minimally-conscious state and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Thomas Cochrane interviews Dr. Damian Cruse about his paper on etiology and covert cognition in the minimally-conscious state. Dr. Stacey Clardy is reading our e-Pearl of the week about Moyamoya disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about cognitive errors or biases that can influence our ability to diagnose. Next week, Dr. Burns will interview Drs Groopman and Hartzband about risk-benefit ratios. The participants had nothing to disclose except Drs. Cochrane, Cruse, Clardy, Burns, Groopman and Hartzband.Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology.Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) AAN policy on pharmaceutical and device industry support and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. John Hutchins about his paper on AAN policy on pharmaceutical and device industry support. Dr. Stacey Clardy is reading our e-Pearl of the week about CSF biomarker in Alzheimer disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about clinical diagnostic reasoning and cognitive errors. Over the following weeks, Dr. Burns will interview Drs Groopman and Hartzband on an additional number of topics with week two about cognitive errors or biases that can influence our ability to diagnose. The participants had nothing to disclose except Mr. Hutchins, Drs. Burns, Clardy, Groopman and Hartzband.Mr. Hutchins is currently the Associate General Counsel of the American Academy of Neurology and General Councel of the American Academy of Neurology Foundation.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

1) Absent brainstem reflexes and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Shin Chien Beh about his paper on a 41-year-old comatose man. Dr. Jennifer Fugate is reading our e-Pearl of the week about gait freezing. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about common central nervous system paraneoplastic disorders. Over the next two weeks, Dr. Karam will interview Dr. Dalmau about other paraneoplastic syndromes in neurology. The participants had nothing to disclose except Drs. Burns, Fugate, Karam and Dalmau.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

1) MuSK myasthenia and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Isabel Illa about her paper on the effect of rituximab in MuSK myasthenia. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Möbius syndrome. In the next part of the podcast Dr. Nandini Muralidharan interviews Dr. Michael Schneck about conflicting values in withdrawal of support. Over the next two weeks, we will have additional interviews regarding ethic issues. The participants had nothing to disclose except Drs. Burns, Illa, Clardy and Schneck.Dr. Illa has received funding for travel from Genzyme Corporation; serves on the editorial board of Neurologia; is listed as author on patent(s) re: Dysferlin detection in monocytes licensed to Athena Diagnostics, Inc.; and receives research support from Grifols, FIS (Fondo de Investigaciones Sanitarias), ISCIII, Ministry of Health (Spain), and Fundacion Gemio. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Schneck serves on data safety monitoring boards for Talecris Biotherapeutics, Chelsea Therapeutics, and Baxter International Inc.; serves on the editorial advisory boards for the Journal of Stroke and Cerebrovascular Disease and Frontiers in Neurocritical Care and Neurohospitalist Care; receives publishing royalties from Continuum; serves on the speakers' bureaus for Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Boehringer Ingelheim, and Pfizer Inc; and receives research support from NMT Medical, Schering-Plough Corp., and the NIH.

1) Transverse myelitis and 2) Topic of the month: Dizziness. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Bragg interviews Dr. Thomas Scott about the evidence-based guideline on transverse myelitis. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Gates' rule of 4 of the brainstem. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Kerber and Robert W. Baloh about Dix-Hallpike maneuver. The participants had nothing to disclose except Drs. Scott, Clardy, Burns, Kerber and Baloh.Dr. Scott has received funding for travel or speaker honoraria from, served on the speakers' bureaus and scientific advisory boards of, and performed consultation work for Acorda Therapeutics Inc., Avanir Pharmaceuticals, Biogen Idec, Novartis, and Teva Pharmaceutical Industries Ltd.; served as an associate editor for BMC Neurology; and has received research support from Biogen Idec, National Multiple Sclerosis Society, Novartis, Pittsburgh Foundation, and Teva Pharmaceutical Industries Ltd.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Kerber has served as a consultant for and received speaker honoraria from the American Academy of Neurology; receives publishing royalties for Clinical Neurophysiology of the Vestibular System, 4th edition (Oxford University Press, 2010); and receives research support from the NIH/NCRR and the Agency for Healthcare Research and Quality.Dr. Baloh has received speaker honoraria from the American Academy of Neurology; serves on the editorial board of Neurology; receives publishing royalties for Clinical Neurophysiology of the Vestibular System, 4th edition (Oxford University Press, 2010); and receives research support from the NIH.

1) Respective epilepsy surgery and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Hamada Hamid about his paper on respective epilepsy surgery. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Post-measles central nervous system syndromes. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about renal insufficiency with final comments on the monthly topic: hypoxic-ischemic encephalopathy. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Goodkin, Hamid, Fugate, Burns and Wijdicks.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; receives royalties from the publication of the book The choking game and other strangulation activities in children and adolescents; and is funded by NIH grants [R01 NS067439 PI and R01 NS48413 PI].Dr. Hamid serves as Managing Editor of the Journal of Muslim Mental Health and receives research support from the National EpiFellows Foundation and the Epilepsy Foundation. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Practice of Neurology 2000-2010 Report and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Ms. Oksana Drogan about the Practice of Neurology 2000-2010 Report. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Ice Pack Test. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about imaging and laboratory testing. For the last week, Dr. Burns will interview Dr. Wijdicks about take-home comments on the monthly topic. The participants had nothing to disclose except Ms. Drogan and Drs. Burns, Fugate, and Wijdicks.Ms. Drogan is a salaried employee of the American Academy of Neurology.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Intravenous dihydroergotamine and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Pearce Korb interviews Dr. Peter Goadsby about his paper on intravenous dihydroergotamine. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Figure 4 sign. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about myoclonic status. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about imaging plus laboratory testing and take-home comments from topic discussed. The participants had nothing to disclose except Drs. Goadsby, Fugate, Burns and Wijdicks.Dr. Goadsby has served as a consultant for or served on a scientific advisory board for Advanced Bionics, Allergan, Inc., Almirall, Amgen, ATI, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CoLucid Pharmaceuticals, Coherex Medical, Inc., Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Medtronic, Inc., MAP Pharmaceuticals, Inc. (makers of an inhaled form of DHE; this consultation period post-dates the period of audit, the period of data collection and initial analysis), Minster Pharmaceuticals plc, Merck & Co., Inc., Neuralieve Inc., NeurAxon Inc., NeuroTherapeutics Pharma, and Pfizer Inc.; receives royalties from the publication of Mechanism and Management of Headache, 7th ed. (Elsevier, 2005); and has received research support from GlaxoSmithKline, Neuralieve Inc., Merck & Co., Inc., Johnson & Johnson, and MAP Pharmaceuticals, Inc. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Guideline update: treatment of essential tremor and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Tiffini Voss interviews Dr. Rodger Elble about the guideline update on treatment of essential tremor. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about 'Burned-out hippocampus' syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about neurologic examination of post-cardiac arrest patients. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about how to translate neurologic examination into a prognosis. The participants had nothing to disclose except Drs. Elble, Fugate, Burns and Wijdicks.Dr. Elble serves on the scientific advisory board for the International Essential Tremor Foundation; has received funding for travel from the Movement Disorders Society; receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Pfizer Inc, Phytopharm, Janssen (Ortho-McNeil), the NIH/NINDS, and the Spastic Paralysis Research Foundation of Kiwanis International; and has acted as an expert witness in a medico-legal proceeding. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Ophelia syndrome and 2) Topic of the month: Hypoxic-ischemic encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennie Taylor interviews Dr. Josep Dalmau about his paper on Ophelia syndrome. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about How long must an athlete wait before returning to play after a concussion? In the next part of the podcast Dr. Ted Burns interviews Dr. Eelco Wijdicks about operational issues related to post-cardiac arrest patients. Over the following weeks, Dr. Burns will interview Dr. Wijdicks about neurologic evaluation of the post-cardiac arrest patient. The participants had nothing to disclose except Drs. Dalmau, Fugate, Burns and Wijdicks.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Wijdicks serves as Editor-in-Chief for Neurocritical Care; and receives royalties for books published by Oxford University Press.

1) Meralgia paresthetica and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chris Klein about his paper on meralgia paresthetica. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week on "Is loss of consciousness required for a diagnosis of concussion?" In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about cranial nerve 6. Next week, Dr. Karam will interview Dr. Kupersmith about Apex syndrome. The participants had nothing to disclose except Drs. Burns, Klein, Clardy, Karam and Kupersmith.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Klein serves on the editorial board of the Journal of Peripheral Nerve Society; serves as a consultant for Pfizer Inc; and receives research support from the NIH/NINDS.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

1) Cardiac arrest survivors and 2) Topic of the month: Neuro-ophthalmology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Rabinstein and Fugate about their paper on cardiac arrest survivors. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about cocaine and beta blockers. In the next part of the podcast Dr. Chafic Karam interviews Dr. Mark Kupersmith about cranial nerve 3. Over the following weeks, Dr. Karam will interview Dr. Kupersmith about other cranial nerves involved in vision. The participants had nothing to disclose except Drs. Burns, Rabinstein, Fugate, Clardy, Karam and Kupersmith.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Rabinstein serves as Section Editor for Year Book Neurology and Neurosurgery Section Editor for Neurocritical Care; has receives research support from CardioNet and Boston Scientific; and receives royalties for books published with Elsevier.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kupersmith serves as Chair of Nordic U10 EY1017281-03, received research support from Nordic U10 EY1017281-03 ECRIPS and has given expert testimony.

1) Early stroke risk and ABCD2 score performance and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Matthew Giles about his paper on early stroke risk and ABCD2 score performance. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about subconjunctival hemorrhages. In the next part of the podcast, Dr. Ted Burns interviews Dr. David Saperstein on B vitamin deficiencies. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Barrett, Giles, Clardy, Burns and Saperstein.Dr. Barrett serves on the editorial board of Neurology®.Dr. Giles has received funding for travel and speaker honoraria from Boehringer Ingelheim; and has received research support from National Institute of Health Research.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Saperstein serves on the scientific advisory boards for Talecris Plasma Resources, CSL Behring and Pfizer Inc; and serves on the speakers' bureau of Lilly.

1) Normal pressure hydrocephalus and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interviews Dr. Bryan Klassen about his paper on normal pressure hydrocephalus. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Hoovers sign. In the next part of the podcast, Dr. Ted Burns interviews GianPietro Sechi about deficiency of thiamine. Next week, you will hear Ted Burns interview David Saperstein on B vitamin deficiencies. The participants had nothing to disclose except Drs. Clardy and Burns.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

1) 60th anniversary editorial and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Robert Griggs about his editorial describing his tenure as Editor for the journal. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Lafora disease. In the next part of the podcast Dr. Matt Barrett interviews Dr. Renee Shellhaas about vitamin D deficiency in children with epilepsy. Next week Matt Barrett will interview Paula Rackoff about steroids and vitamin D, Calcium and osteoporosis. The participants had nothing to disclose except Drs. Burns, Griggs, Clardy, and Shellhaas.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Griggs serves as Chair of Executive Committee of the Muscle Study Group, which receives support from pharmaceutical companies; has served on scientific advisory boards for The National Hospital Queen Square and PTC Therapeutics, Inc.; serves on the editorial boards of NeuroTherapeutics and Current Treatment Opinions in Neurology; receives royalties from the publication of Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition (W.B. Saunders Company, 2000, 2004, 2007, and 2010) and Cecil Textbook of Medicine, 24th Edition (Saunders, 2000, 2004, 2008, and 2010, in press); and has received research support from TaroPharma and the NIH/NINDS, the FDA, and the Muscular Dystrophy Association.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Shellhaas receives research support from the NIH, University of Michigan through the Janette Ferrantino Investigator Award 2010 and Charles Woodson Pediatric Biostatics Fund Major Award 2011, and Child Neurology Foundation, Shields Fellowship Award 2009-2011.

1) Functional psychogenic symptoms and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Michael Sharpe about his paper on guided self-help for functional (psychogenic) symptoms. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Melkersson-Rosenthal syndrome. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 2. Over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, Mark Eckman and Tom Brott about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Sharpe, Burns, Fugate, Kissela, Sacco and Goldstein.Dr. Sharpe serves as an Associate Editor for the Journal of Psychosomatic Research and on the editorial boards of General Hospital Psychiatry, Psychological Medicine, and Psychosomatics; serves as an independent medical advisor to AEGON Insurance; receives publishing royalties from Oxford University Press, Wiley-Blackwell and Churchill Livingstone and serves on a DSM5 work group for the American Psychiatric Association; is a member of Council of the Academy of Psychosomatic Medicine and receives research support from the Medical Research Council UK and Cancer Research UK.Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).

1) Cost-effectiveness of disease-modifying therapy and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan with Dr. Katia Noyes about her paper on disease-modifying therapy for multiple sclerosis. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about numb chin syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about peroneal neuropathy. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Keegan, Noyes, Fugate and Burns.Dr. Noyes serves on the scientific review panel for the National Multiple Sclerosis Society (NMSS) and has received research support from Biogen Idec, Boston Scientific, the NIH, and the NMSS.Dr. Keegan serves as a Section Editor for Neurology® and as Chief Editor for eMedicine; and has served as a consultant for Novartis and the FDA.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Exercise effect on Parkinson disease and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan with Dr. Eric Ahlskog about his paper on vigorous exercise effect on Parkinson disease. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Beevor's sign. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about radial neuropathies. Next week, Dr. Burns will interview Dr. Stewart about another common mononeuropathy. The participants had nothing to disclose except Drs. Morgan, Ahlskog, Fugate and Burns.Dr. Morgan received research support from National Parkinson Foundation, Pharmaceutical Strategies Group, HealthCare Solutions Group, Merz Pharmaceuticals, LLC, NIH (NET-PD LS-1 [sub-investigator], Acadia Pharmaceuticals, Inc., Boehringer Ingelheim, EMD Serono, GlaxoSmithKline, and Solvay Pharmaceuticals Inc., serves on speakers' bureaus for Boehringer Ingelheim, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd. and National Parkinson Foundation, served as a consultant for Life Cycle Pharma, Lundbeck, National Parkinson Foundation, and Teva Pharmaceutical Industries Ltd.. Dr. Ahlskog received the Fred Springer Award from the American Parkinson's Disease Association; serves on the editorial boards of Parkinsonism and Related Disorders and Clinical Neuropharmacology; receives royalties from the publication of The Parkinson's Disease Treatment Book (Oxford University Press, 2005), Parkinson's Disease Treatment Guide for Physicians (Oxford University Press, 2009), Parkinson's Disease and Movement Disorders (Humana Press, 2000), and Surgical Treatment of Parkinson's Disease and Other Movement Disorders (Humana Press, 2003); and receives research support from NIH/NINDS.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Diagnosed multiple sclerosis and clinically isolated syndrome and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chris Scherer with Dr. Stine Marit Moen about her paper on newly diagnosed multiple sclerosis and clinically isolated syndrome.In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about hung-up reflex. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about ulnar neuropathies. Over the subsequent two weeks, Dr. Burns will interview Dr. Stewart about other common mononeuropathies. The participants had nothing to disclose except Drs. Moen, Fugate and Burns.Dr. Moen has received funding for travel from Biogen Idec; and has received research support from Biogen Idec, the South-Eastern Norway Regional Health Authority, Odd Fellow Research Foundation for Multiple Sclerosis, the Endowment of K. and K.H. Hemsen, and the Endowment of Fritz and Ingrid Nilsen.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Outcome of comatose patients and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Flaherty interviews Dr. Eelco Wijdicks about his paper on predicting outcome of comatose patients. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about eight-and-a-half-syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about median neuropathies. Over the subsequent three weeks, Dr. Burns will interview Dr. Stewart about other common mononeuropathies. The participants had nothing to disclose except Drs. Flaherty, Wijdicks, Fugate and Burns.Dr. Flaherty is a consultant for Boehringer Ingelheim, received research support from PhotoThera, Inc. and is funding by NIH grants 2D50NS044283-06 [PI}, NIH R01 NS030678 [Co-I], NIH R01 NS 036695 [Co-I], and NIH R01 NS044876 [Co-I).Dr. Wijdicks receives honoraria from Springer for his role as the Editor-in-Chief of Neurocritical Care and receives royalties from books published with Oxford University Press. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Frontotemporal dementia and 2) Topic of the month: Featured speakers from the AAN Meeting. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Keith Jospehs about his paper on frontotemproal dementia with motor neuron disease. In the next segment, Dr. Sarah Song is reading our e-Pearl of the week about SMART syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Dennis Dickson about receiving the Potamkin Prize for Research in Pick's Alzheimer's and related diseases at the AAN Meeting. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Burns, Josephs, Song, Espay and Dickson.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Josephs receives research support from the NIH (NIDCD, NIA) and the Dana Foundation.Dr. Song served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves on scientific advisory boards for Boehringer Ingelheim and Solvay Pharmaceuticals, Inc.; serves on the editorial advisory board for The European Neurological Journal; has received speaker honoraria from UCB/SCHWARZ PHARMA, Medtronic, Inc., and Novartis; has received honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society; has served on speakers' bureaus for UCB/SCHWARZ PHARMA and Novartis; receives/has received research support from Medtronic, Inc., Allergan, Inc., CleveMed, the KL2 Research Scholars mentored career development award, and NIH Institutional Clinical and Translational Science Award (RR026315-02), Dean Scholar's Award - University of Cincinnati, Davis Phinney Foundation, and the Michael J Fox Foundation. Dr. Dickson serves on the editorial boards of the American Journal of Pathology, Journal of Neuropathology and Experimental Neurology, Brain Pathology, Neurobiology of Aging, Journal of Neurology Neurosurgery and Psychiatry, Annals of Neurology, and Neuropathology; and receives research support from the NIH and Cure PSP/Society for PSP.

1) Voltage sensor mutations and 2) Topic of the month: Featured speakers from the AAN Meeting. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Cannon about his paper on voltage sensor mutations. In the next segment, Dr. Sarah Song is reading our e-Pearl of the week about Cogan's sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Robert Griggs about his Presidential Lecture. The LOTWs for the next three weeks of May will continue with more featured speakers from the AAN Meeting being interviewed. The participants had nothing to disclose except Drs. Burns, Cannon, Song, Espay and Griggs.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cannon serves on the scientific advisory board for Telethon (Italy); serves on the editorial advisory board of the Journal of General Physiology; and receives research support from the NIH/NIAMS. Dr. Song served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves on scientific advisory boards for Boehringer Ingelheim and Solvay Pharmaceuticals, Inc.; serves on the editorial advisory board for The European Neurological Journal; has received speaker honoraria from UCB/SCHWARZ PHARMA, Medtronic, Inc., and Novartis; has received honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society; has served on speakers' bureaus for UCB/SCHWARZ PHARMA and Novartis; receives/has received research support from Medtronic, Inc., Allergan, Inc., CleveMed, the KL2 Research Scholars mentored career development award, and NIH Institutional Clinical and Translational Science Award (RR026315-02), Dean Scholar's Award - University of Cincinnati, Davis Phinney Foundation, and the Michael J Fox Foundation. Dr. Griggs serves as Chair of Executive Committee of the Muscle Study Group, which receives support from pharmaceutical companies; has served on scientific advisory boards for The National Hospital Queen Square and PTC Therapeutics, Inc.; serves on the editorial boards of NeuroTherapeutics and Current Treatment Opinions in Neurology; receives royalties from the publication of Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition (W.B. Saunders Company, 2000, 2004, 2007 and 2010) and Cecil Textbook of Medicine, 24th Edition (Saunders, 2000, 2004, 2008 and 2010 in press); has received research support from TaroPharma and the NIH (NINDS T32 NS07338 [PI and preceptor], 2 U54 NS059065-06 [PI], R01 NS045686-05 [PI], and NINDS 525326 [Co-PI]), the FDA, and from the Muscular Dystrophy Association.